Arbutus Biopharma Investor Relations Material
Latest events
Q4 2023
Arbutus Biopharma
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Arbutus Biopharma Corporation
Access all reports
Arbutus Biopharma Corporation is a biopharmaceutical company, which focuses on the development of novel therapeutics for chronic hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. The Company’s lead product candidate, ABT-493 is a first-in-class treatment for chronic hepatitis B virus (HBV) infection. ABT-493 has been granted Qualified Infectious Disease Product (QIDP) designation by U.S. Food and Drug Administration (FDA). It distributes its products in US hospitals, children's hospitals, acute care hospitals, outpatient clinics, home health care agencies etc.
Key slides for Arbutus Biopharma Corporation
Corporate Presentation
Arbutus Biopharma Corporation
Corporate Presentation
Arbutus Biopharma Corporation
Latest articles
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Larry Page: The Mastermind Behind Google
Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.
24 Apr 2024
Mark Leonard: The Mysterious Brain Behind Constellation Software
Information about Mark Leonard is scarce, and one of the only ways to “get to know” him is through his shareholder letters. Join us in an attempt to do so.
24 Apr 2024
Ticker symbol
Country
🇺🇸 United States